KR101444067B1 - Manufacturing method of drug loaded polyurethane composite membrane - Google Patents

Abstract

The present invention relates to a method for manufacturing a drug loaded polyurethane composite membrane, comprising the steps of: injecting a drug solution into a polyurethane solution; forming a polyurethane membrane with a target thickness by electrospinning the polyurethane solution into which the drug solution is injected; and obtaining a polyurethane composite membrane in which silicon is complexed by immersing the polyurethane membrane into silicon solution. The polyurethane composite membrane, in which the drug manufactured by the present invention is mounted, has flexibility and can act as a drug delivery system by mounting the drug.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a method for manufacturing a polyurethane-

The present invention relates to a process for producing a polyurethane-based composite membrane, and more particularly, to a process for producing a polyurethane-based composite membrane having a drug that is flexible and has a drug loaded thereon and is capable of acting as a drug delivery system will be.

Drug delivery system technology, which improves drug delivery system and enhances drug efficacy, is drawing attention from the medical community. In the US and Japan, since the late 1980s, companies such as pharmaceutical companies have focused on the development of drug delivery systems along with the development of new drug delivery technologies, in combination with nanotechnology. Korea has also achieved comprehensive achievements in the development of drug delivery system technology while establishing comprehensive research systems such as pharmaceutical companies, academia and research institutes in order to advance into the global market and create pharmaceutical fields. Generally, medicines are used to treat diseases or damaged parts of the human body. Drug delivery systems are being used for maximizing the therapeutic effect and minimizing the side effects of the human body. Drug delivery systems are commonly referred to as simple formulations of medicines and formulations with high functionality. They are applied to patients through various routes of the body including oral, injection, transdermal, mucosal, and transplant. Drugs are shown to have a therapeutic effect by binding to receptors distributed in disease sites. The ideal method of administration is that the drug appears immediately upon application of the drug, maintains a constant blood concentration during the treatment period, is immediately withdrawn from the body after the drug is discontinued at the end of treatment. Therefore, new drug delivery methods have been actively studied for improving the bioavailability of the administered drug, improving the therapeutic effect, and increasing the adherence of the drug.

SUMMARY OF THE INVENTION The present invention provides a method for manufacturing a polyurethane-based composite membrane, which is manufactured using polyurethane, has flexibility and is equipped with a drug and is capable of acting as a drug delivery system.

The present invention relates to a method for preparing a polyurethane membrane, comprising the steps of injecting a drug solution into a polyurethane solution, electrospinning the polyurethane solution injected with the drug solution to form a polyurethane membrane of a desired thickness, and immersing the polyurethane membrane in a silicone solution And a step of obtaining a polyurethane-based composite membrane in which silicon is complexed with the polyurethane-based composite membrane.

The polyurethane solution may be a solution in which polyurethane is dissolved in a solvent in which N, N-dimethylformamide and tetrahydrofuran are mixed in a volume ratio of 1: 0.1 to 10, and the polyurethane is added to the polyurethane solution It is preferably contained in an amount of 0.1 to 30 parts by weight based on 100 parts by weight of the mixed solvent of N, N-dimethylformamide and tetrahydrofuran.

The silicon solution may be a solution containing silicon and xylene, and the silicon and the xylene may be mixed in a volume ratio of 1: 0.1 to 20.

The drug solution may be an anticancer drug solution in which docetaxel is dissolved in dimethicyl sulphoxide.

The docetaxel may be contained in the drug solution at a concentration of 0.1 to 100,000 ppm.

The drug solution is preferably injected in an amount of 0.0001 to 10 parts by weight per 100 parts by weight of the polyurethane solution.

The polyurethane membrane is preferably formed to a thickness of 5 to 300 mu m.

According to another aspect of the present invention, there is provided a method of preparing a polyurethane membrane, comprising: electrospinning a polyurethane solution to form a polyurethane membrane having a desired thickness; injecting a drug solution into the silicone solution; To obtain a polyurethane-based composite membrane in which silicon is complexed. The present invention also provides a method for producing a polyurethane-based composite membrane on which a drug is loaded.

The polyurethane solution may be a solution in which polyurethane is dissolved in a solvent in which N, N-dimethylformamide and tetrahydrofuran are mixed in a volume ratio of 1: 0.1 to 10, and the polyurethane is added to the polyurethane solution It is preferably contained in an amount of 0.1 to 30 parts by weight based on 100 parts by weight of the mixed solvent of N, N-dimethylformamide and tetrahydrofuran.

The silicon solution may be a solution containing silicon and xylene, and the silicon and the xylene may be mixed in a volume ratio of 1: 0.1 to 20.

The drug solution may be an anticancer drug solution in which docetaxel is dissolved in dimethicyl sulphoxide.

The docetaxel may be contained in the drug solution at a concentration of 0.1 to 100,000 ppm.

The drug solution is preferably injected in an amount of 0.0001 to 10 parts by weight based on 100 parts by weight of the silicone solution.

The polyurethane membrane is preferably formed to a thickness of 5 to 300 mu m.

According to the present invention, the polyurethane-based composite membrane on which the drug prepared according to the present invention is loaded has flexibility and can be loaded with a drug to act as a drug delivery system.

Polyurethane composite membranes with silicone complexes may not change the characteristics of membranes even if they are immersed in buffer solution for a long time. Polyurethane composite membranes complexed with silicon can contain large quantities of drug because the drug is contained not only between the pores of the polyurethane membrane but also between the silicones and can be released for a long time. In the case of a polyurethane composite membrane complexed with silicone, the drug contained in the pore is slowly poured out slowly, and the drug is released (slowly releasing) and can be released in a suitable amount for a long time.

1A and 1B are scanning electron microscope (SEM) photographs of a 20 탆 thick polyurethane membrane (PU-1) prepared using electrospinning according to an experimental example, and Figs. 1C and 1D are photographs 1E and 1F are scanning electron microscope (SEM) photographs of a polyurethane membrane (PU-3) having a thickness of 40 μm. FIG. 2 is a scanning electron microscope (SEM) image of a polyurethane membrane (PU-
2A and 2B are SEM photographs of a 20 탆 thick polyurethane membrane (PU-1) prepared using electrospinning according to Experimental Examples, and Figs. 2C and 2D are SEM photographs of a polyurethane composite membrane 2E and 2F are SEM micrographs of polyurethane composite membrane (PU / Si-2), and FIGS. 2G and 2H are SEM images of poly (SEM) of urethane composite membrane (PU / Si-3).
FIGS. 3A and 3B are graphs showing results obtained by coating a polyurethane solution on a glass plate and drying it in an oven (OPD), a polyurethane membrane (EPD) prepared by electrospinning, and a membrane complexed with silicone on a polyurethane membrane prepared by electrospinning EPDS).
4A and 4B are graphs showing the results obtained by coating a polyurethane solution on a glass plate and drying it in an oven (OPD), a polyurethane membrane (EPD) prepared by electrospinning, and a membrane obtained by compounding silicon on a polyurethane membrane prepared by electrospinning EPDS). ≪ / RTI >

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. However, it should be understood that the following embodiments are provided so that those skilled in the art will be able to fully understand the present invention, and that various modifications may be made without departing from the scope of the present invention. It is not.

Hereinafter, the term " nano " refers to a size in nanometers (nm), which means a size of 1 to 1,000 nm.

According to the definition of IUPAC (International Union of Pure and Applied Chemistry), the pore size of the porous body is divided into three types according to the pore diameter of the porous material. The micropore has a pore diameter of 2 nm or less, the mesopore has a pore diameter And macropores of 50 nm or more are defined. Hereinafter, the term "nano pores" means micro pores, mesopores and macropores, and means pores having a pore diameter of 1 to 1,000 nm.

In the following, silicon means silicon, which is an organic compound containing silicon.

In the present invention, a polyurethane membrane having flexibility is prepared using polyurethane, and a method of composing the polyurethane membrane with the polymer is provided to control the release time of the drug.

A method for preparing a drug-loaded polyurethane composite membrane according to an embodiment of the present invention comprises the steps of injecting a drug solution into a polyurethane solution, electrospinning a polyurethane solution injected with the drug solution, To form a polyurethane membrane, and immersing the polyurethane membrane in a silicon solution to obtain a polyurethane-based composite membrane in which silicon is complexed.

The polyurethane solution may be a solution in which polyurethane is dissolved in a solvent in which N, N-dimethylformamide and tetrahydrofuran are mixed in a volume ratio of 1: 0.1 to 10, and the polyurethane is added to the polyurethane solution It is preferably contained in an amount of 0.1 to 30 parts by weight based on 100 parts by weight of the mixed solvent of N, N-dimethylformamide and tetrahydrofuran.

The silicon solution may be a solution containing silicon and xylene, and the silicon and the xylene may be mixed in a volume ratio of 1: 0.1 to 20.

For example, the drug solution may be an anticancer drug solution in which docetaxel is dissolved in dimethicyl sulphoxide.

The docetaxel may be contained in the drug solution at a concentration of 0.1 to 100,000 ppm.

The content of the drug solution is set in accordance with the intended use and the desired release time. For example, the drug solution is preferably injected in an amount of 0.0001 to 10 parts by weight per 100 parts by weight of the polyurethane solution.

The polyurethane membrane is preferably formed to a thickness of 5 to 300 mu m.

According to another preferred embodiment of the present invention, there is provided a method for preparing a polyurethane-based composite membrane on which a drug is loaded, comprising the steps of: electrospinning a polyurethane solution to form a polyurethane membrane having a desired thickness; And immersing the polyurethane membrane in the silicon solution into which the drug solution is injected to obtain a polyurethane composite membrane in which silicon is complexed.

The polyurethane solution may be a solution in which polyurethane is dissolved in a solvent in which N, N-dimethylformamide and tetrahydrofuran are mixed in a volume ratio of 1: 0.1 to 10, and the polyurethane is added to the polyurethane solution It is preferably contained in an amount of 0.1 to 30 parts by weight based on 100 parts by weight of the mixed solvent of N, N-dimethylformamide and tetrahydrofuran.

The silicon solution may be a solution containing silicon and xylene, and the silicon and the xylene may be mixed in a volume ratio of 1: 0.1 to 20.

For example, the drug solution may be an anticancer drug solution in which docetaxel is dissolved in dimethicyl sulphoxide.

The docetaxel may be contained in the drug solution at a concentration of 0.1 to 100,000 ppm.

The content of the drug solution is set according to the intended use and the desired release time. For example, the drug solution is preferably injected in an amount of 0.0001 to 10 parts by weight based on 100 parts by weight of the silicone solution.

The polyurethane membrane is preferably formed to a thickness of 5 to 300 mu m.

Hereinafter, experimental examples according to the present invention will be specifically shown, and the present invention is not limited by the following experimental examples.

A urethane bond is formed when an alcohol having an active hydroxyl group and an isocyanate having an isocyanate group generate reaction heat by an addition polymerization reaction. Polyurethane refers to a polymer substance containing a urethane bond formed by using polyol and isocyanate as main materials. It is produced by the reaction of a polyisocyanate (-NCO) with a polyol (-OH). Here, polyol refers to a compound having active hydrogens such as -OH and -NH _{2 in the} molecule, and initially polyester polyol was mainly used. However, due to development of petrochemical industry, propylene oxide (PO), ethylene oxide Oxide (EO) has been mass-produced and supplied, more than 90% of polyester polyols are currently used. Urethane bond was shown in Reaction Formula 1 below, and polyurethane formation reaction was shown in Reaction Formula 2. In order to obtain an industrially useful polyurethane, many kinds of raw materials and additives are used in addition to the main polyisocyanate and polyol to form urethane.

[Reaction Scheme 1]

[Reaction Scheme 2]

Due to its excellent properties, polyurethane is used in various applications to manufacture products that can be always encountered in our daily lives such as shoes, sofas, beds, cars, refrigerators, building materials, flooring,

Electrospinning is a method of spinning in the form of a fiber instantaneously using a polymer of low viscosity, one spin coating the solution to adhere to the surface of the other collector, the main subject of the electric field being a polymer Which causes the solution to stick due to its own tension. The electric radiator is largely composed of three parts. A high molecular weight solution, a high voltage part, and a fiber and particle laminating part (collector) for applying a high voltage to the molten polymer. When the strength of the dry magnetic field is equal to the surface tension of the polymer solution, the charged polymer solution is formed on the tip portion. If the voltage exceeds the surface tension of the polymer, the charged polymer droplets are not stabilized and dispersed in the ground direction . The dispersed polymer solution is concentrated on the collector in the form of fibers and particles. The potential difference depends on the characteristics of the spinning solution, the molecular weight of the polymer, and the viscosity. If the distance between the spinneret and the collector is short, evaporation of the solvent is not enough, so that the spinning fiber tangles not only with the collector but also with the fibers. The parameters of the electrospinning include the characteristics of the solution, the distance between the nozzle and the collector, the field strength, the spinning time, and the spinning environment. The spinning pattern includes droplet, spout, .

Drug delivery system is defined as technology to optimize drug treatment by designing dosage form to efficiently deliver the necessary amount of drug to minimize the side effect of existing drug and maximize efficacy for treatment of body disease . The blood concentration is the most important factor for manifesting the therapeutic effect, and it is a field to design formulations for drug delivery such as tablets, capsules, injections, patches, mucosal agents, inhalants, Core technologies include drug release rate control techniques, poorly soluble drug solubilization techniques, nanoparticle carrier technology, targeting technology, peptide and protein drug delivery technology, and gene delivery technology. The action of the administered drug should first be such that the drug can maintain a reasonable amount of concentration in our body, and second, since our body is an automatic system of stimulus-response that only reacts when necessary, do. Finally, drugs should only be delivered to the affected tissues or cells to minimize side effects.

Drug delivery systems are divided into a sustained drug release system, a controlled release system, and a targeted drug delivery system. The sustained drug release system is a formulation designed to reduce the bioavailability by slowing the release rate of the drug or to reduce the problems of drug absorption too slowly or too quickly in vitro and the controlled release system controls the concentration of the target site The actual treatment effect is controlled. Targeted drug delivery systems are formulations developed to selectively deliver the drug to the site of need and then maintain the required concentration for the required period of time. It is possible to suppress the distribution to unnecessary parts and to reduce side effects. Targeted drug-carrier complexes should be delivered in a stable form to the target site containing sufficient quantities of drug, and the drug should be released according to the planned rate pattern after reaching the target site. After administration, they must selectively reach the target site and accumulate. The carrier should be biodegradable or at least not bioaccumulative, antigenic and toxic. Drug carriers include molecular carriers, microporous carriers, carriers using biological cognition, and external inductive carriers (magnetic carriers, external release controlled carriers).

1. Manufacture of polyurethane composite membranes by electrospinning

(1) Preparation of polyurethane solution

As a solvent for the polyurethane solution, N, N-dimethylformamide (DMF, sigma aldrich) and tetrahydrofuran (THF, sigma aldrich) were used and the polymer Chronoflex C 80A (ChronoFlex C 80A, advansource bio-materials). After mixing N, N-dimethylformamide (DMF) and tetrahydrofuran (THF) at a volume ratio of 1: 1, 10% by weight of Chronoflex C 80A (total content of DMF and THF of 90% by weight and Chronoflex C 80A was added in an amount of 10% by weight), and heat was applied to dissolve uniformly.

(2) Manufacture of polyurethane composite membranes

The polyurethane membrane was prepared by mixing the drug with the polyurethane solution and electrospinning it. In the experimental example of the present invention, the silicon solution and the xylene were mixed at a volume ratio of 1: 2 in order to make all the membranes have a thickness of 20 μm, but the concentration of the silicon solution can be controlled according to the desired porosity. The silicone solution was a mixture of MED-6640 (nusil) Part A and Part B. Part A and Part B were mixed at a volume ratio of 1: 1 for 2 hours, and then the viscosity was lowered by adding xylene (sigma aldrich) to the mixture. The silicon solution mixed with Part A and Part B and xylene were mixed in a volume ratio of 1: 2.

2. Drug injection and release method

(1) Drug loading method

The drug was docetaxel (D-1000, LC Lab.), Which is mainly used for the treatment of breast, ovarian, prostate, etc. Since docetaxel has a strong lipophilic property and is almost insoluble in water, it is dissolved in a polyurethane solution when the electrospun polyurethane drug is injected and adjusted to a concentration of 5000 ppm. In the case of a composite membrane in which a polymer is complexed, an electrospun polyurethane membrane loaded with the drug is immersed in a silicone solution.

(2) Standard drug preparation method

A standard solution was made to compare the solution released from the prepared membrane and to determine the peak of the drug in High Performance Liquid Chromatography (hereinafter referred to as 'HPLC'). Standard solutions were made to be loaded with 50 ppm and 25 ppm, respectively, in buffer (PBS, Sigma aldrich). Since docetaxel does not dissolve in PBS (phosphate buffer solution), it dissolves 0.001 g in 0.5 ml of dimethlysulfoxide, and 19.5 ml of PBS is prepared. 1 ml of 25 ppm is taken from 50 ppm solution and 1 ml of buffer solution is prepared .

(3) Drug release method

Drug release is an experiment that can confirm how much drug is released in a drug-injected membrane for a given time.

10 ml of a buffer solution having a pH of 7.2 was added to the vial, and the drug-injected membrane was immersed and placed in a shaker. At this time, the condition was set at 36.5 ± 5 ° C, which is the same temperature as the body (body), and set at 100 rpm. The measurement time (10 to 120 minutes, 3 to 20 hours, 2 to 90 days / total about 90 days) was measured at intervals of 10 minutes between the first 10 and 120 minutes and every hour between 3 and 20 hours, Between 2 and 90 days were measured every day.

After the drug release measurement was completed, 10 ml of the release solution was all taken, transferred to another vial, and stored frozen. For each of the other effluent samples, 10 mL of buffered solution and buffer were injected into a new vial and placed in a shaker to measure drug release.

These freeze-thawed vials were then measured and compared with the standard sample using HPLC to determine the calculated drug loading and actual drug release.

3. Physical and morphological characteristics of polyurethane membranes and composite membranes prepared by electrospinning

(1) Physical and morphological characteristics of polyurethane membranes prepared by electrospinning

The polyurethane membrane prepared by electrospinning has a thickness of 20 to 40 탆, a density of 0.32 to 0.35 g / cm ³ and a porosity of 60 to 70%. PU-1 is 20 탆 and PU-2 is 30 Mu m, and PU-3 is 40 mu m, and the density is shown in Table 1. The scanning electron microscope (SEM) photographs are compared with Figs. 1A to 1F. 1A and 1B show a polyurethane membrane (PU-1) with a thickness of 20 μm, FIGS. 1C and 1D show a polyurethane membrane (PU-2) with a thickness of 30 μm, 1f shows a polyurethane membrane (PU-3) having a thickness of 40 mu m. The polyurethane membranes prepared according to the experimental examples were flexible and had high modulus of elasticity.

Sample thickness
(mm) weight
(g) area
(cm ² ) density
(g / cm ³⁾ Porosity
(%) PU-1 0.02 0.0056 7.5 0.3544 65.82 PU-2 0.03 0.0078 7.5 0.3250 68.75 PU-3 0.04 0.0102 7.5 0.3481 66.21

The polyurethane membrane used for drug release had a thickness of 20 μm, a density of 0.38 g / cm ³ and a porosity of 63%. The amount of injected drug was 271.43 μg, which was released for a total of 90 days. During the first 10 days, Was released, but a small amount of drug was released slowly over the next 80 days. 3A to 4B show drug release results by HPLC.

(2) Physical and morphological characteristics of polyurethane composite membranes prepared by electrospinning

In the case of the polyurethane composite membrane, the polyurethane membrane having a thickness of 20 탆 was made to have a thickness of 20 탆, a density of 0.7 to 0.9 g / cm ³ and a porosity of ^{5 to} 24%. Silicone solutions were classified as PU / Si-1, PU / Si-2 and PU / Si-3 depending on the concentration of silicone. PU / Si-1 is a mixture of MED-6640 (Nusil) part A and part B in a volume ratio of 1: 1 and xylene in a 1: 4 volume ratio. PU / Si- 6640 (Nusil) PU / Si-3 is a mixed solution of MED-6640 (Nusil) Part A and Part A, and PU / Si-3 is a mixture of Part A and Part B in a volume ratio of 1: B were mixed in a volume ratio of 1: 1 and xylene at a volume ratio of 1: 1, and the density was shown in Table 2, and the polyurethane composite membrane prepared by electrospinning was observed under a scanning electron microscope (SEM) are shown in Figs. 2A to 2H. 2A and 2B show a polyurethane membrane (PU-1) with a thickness of 20 μm, FIGS. 2C and 2D show a polyurethane composite membrane (PU / Si-1) (PU / Si-2), and Figs. 2G and 2H show a polyurethane composite membrane (PU / Si-3).

Sample thickness
(mm) weight
(g) area
(cm ² ) density
(g / cm ³⁾ Porosity
(%) PU / Si-1 0.02 0.010 7.5 0.707 24.29 PU / Si-2 0.02 0.011 7.5 0.747 20.00 PU / Si-3 0.02 0.013 7.5 0.887 5.00

The polyurethane membrane fabricated by electrospinning can confirm the pores in the form of fibers. Since the surface of the composite membrane coated with silicon is coated with silicon, it is not possible to observe the pores in detail, but it can be confirmed that the pores are filled. The composite membrane prepared according to the Experimental Example was flexible and resistant to moisture.

The polyurethane composite membrane used for drug release had a thickness of 20 μm, a density of 0.78 g / cm ³ and a porosity of 21%. The amount of injected drug was 280.95 μg, and the drug was released for a total of 90 days such as a polyurethane membrane. A large amount of drug was released, but then slowly released a small amount of drug. 3A to 4B show drug release results by HPLC.

4. Control of drug release characteristics

(1) Control of drug release properties of polyurethane membranes and composite membranes prepared by electrospinning

The HPLC measurement conditions used in the experiment were a YMC-pack ODS-A column, a size of 4.6 nm x 250 mm, a solvent, a 4: 6 ratio of tertiary distilled water and acetonitrile, and a flow rate of 1 ml / min . The detector used was 210nm UV detector and the dose was 50.0μ since the amount of drug was very small.

The results of the analysis of the buffer solutions and the standard solutions of 50 ppm and 25 ppm were not detected in the buffer solution, but the peaks which are prominent at 50 ppm and 25 ppm were drugs, and the solvent used for drug release was analyzed as a buffer solution Results The buffer solution was detected at about 2.1 seconds, and the peak was detected at about 2.5 seconds for dimethicyl sulphoxide and about 6.7 seconds for docetaxel.

(2) Control of drug release characteristics of polyurethane membrane and composite membrane

The polyurethane membrane had a thickness of 20 탆, a density of 0.38 g / cm ³ and a porosity of 63%. The amount of the drug injected into the solution before the electrospinning was 271.43 이며, As a result, the drug was released for about 80 days, and about 55% of the total loaded drug was released.

The polyurethane composite membrane had a thickness of 20 탆, a density of 0.77 g / cm ³ , and a porosity of 21%. The polyurethane membrane was dip-coated on the silicone solution. The amount of drug injected was 280.95 μg and the drug release lasted for a total of 90 days. After 5 days, a large amount of drug was not released but a small amount was released.

As a comparative sample, a polyurethane solution mixed with a drug was coated on a glass plate to prepare a membrane, and the result of drug release was compared by HPLC. The thickness was 19 μm, the density was 0.67 g / cm ³ , the porosity was 60% Respectively.

It was similar to the composite membrane complexed with silicone. The drug was released in small amounts and lasted for a total of 90 days.

FIGS. 3A and 3B are graphs showing results obtained by coating a polyurethane solution on a glass plate and drying it in an oven (OPD), a polyurethane membrane (EPD) prepared by electrospinning, and a membrane complexed with silicone on a polyurethane membrane prepared by electrospinning EPDS). In FIG. 3A, the peak of the buffer solution, dimethysulfoxide, and docetaxel was confirmed by HPLC analysis, and the drug peak was enlarged in FIG. 3B.

Figures 4A and 4B show the results of calculating the drug release amount and time. 4A and 4B are graphs showing the results obtained by coating a polyurethane solution on a glass plate and drying it in an oven (OPD), a polyurethane membrane (EPD) prepared by electrospinning, and a membrane obtained by compounding silicon on a polyurethane membrane prepared by electrospinning (▲: OPD, ●: EPD, ■: EPDS) showing the drug elution rate of EPDS.

In the experimental example of the present invention, the polyurethane membrane prepared by drying in an oven, a polyurethane membrane prepared by electrospinning, and a composite membrane composed of silicone were fabricated, and the amount of loading of the polymer and the change of time according to the type of polymer were examined.

Polyurethane and silicone are water soluble, moisture resistant, both flexible and resilient, so the characteristics of the membrane may not change even when immersed in buffer for a long time.

As a drug used in the experimental example of the present invention, docetaxel was dissolved in a polymer solution because it was not soluble in water and complexed. DMF and THF were used as the polyurethane solvent, and xylene was used for the silicone solution. As a result, the drug was contained not only between the pores but also between the polymers, so it could contain a large amount of drug, and the release was possible for a long time.

The polyurethane membranes prepared by electrospinning and the composite membranes prepared by the siliconization of the polysilicon membranes were found to quickly disappear at first but after a certain period of time, the membranes were found to slowly last a small amount of time. On the other hand, The drug can be released to some extent and released over a long period of time. In the experimental example of the present invention, the thickness of all the membranes to be used in the drug release experiment was adjusted to 20 탆 in order to adjust the conditions constantly, but it is expected that the efficiency will be further improved by adjusting the thickness of the polymer in order to release the drug for a desired time.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, This is possible.

Claims (9)

delete Electrospinning a polyurethane solution to form a polyurethane membrane of a desired thickness;
Injecting a drug solution into the silicon solution; And
And immersing the polyurethane membrane in the silicon solution into which the drug solution is injected to obtain a polyurethane composite membrane in which silicon is complexed,
The polyurethane solution is a solution in which polyurethane is dissolved in a solvent in which N, N-dimethylformamide and tetrahydrofuran are mixed in a volume ratio of 1: 0.1 to 10,
The polyurethane is contained in the polyurethane solution in an amount of 0.1 to 30 parts by weight based on 100 parts by weight of the mixed solvent of N, N-dimethylformamide and tetrahydrofuran,
The polyurethane membrane is formed to a thickness of 5 to 300 탆,
The silicon solution is a solution containing silicon and xylene,
The silicon and the xylene are mixed in a volume ratio of 1: 0.1 to 20,
Wherein the drug solution is injected in an amount of 0.0001 to 10 parts by weight based on 100 parts by weight of the silicone solution.
delete delete [Claim 3] The method according to claim 2, wherein the drug solution is an anticancer drug solution in which docetaxel is dissolved in dimethylsulfoxide.
[6] The method of claim 5, wherein the docetaxel is contained in the drug solution at a concentration of 0.1 to 100,000 ppm.
delete delete delete

Images